Astellas Pharma Inc.
Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy;…
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2023-07-10 | Daniel S. Goldman · D-NY | House | Sold | $15,001 - $50,000 |
| 2023-02-27 | Daniel S. Goldman · D-NY | House | Bought | $15,001 - $50,000 |
| 2023-01-13 | Daniel S. Goldman · D-NY | House | Sold | $1,001 - $15,000 |
| 2020-03-18 | Greg Gianforte · R-MT | House | Bought | $15,001 - $50,000 |
Markers sit on the transaction date the member disclosed, snapped to the nearest close on the chart. They are not the date the public found out — that came later, and the gap is its own page. Every marker is listed by name in the table above.